This report analyzes the merger and acquisition (M&A) activity in Q1 2025 in the Pharma sector.
The global pharma sector in Q1 2025 witnessed deals worth $37.7 billion, an increment of 100.4% compared to Q4 2024. In terms of deal volume, there was a decline of 1.4% to 142 M&A deals in Q1 2025. Oncology was the top therapy area with 63 deals, an increase of 6.8% YoY.
The global pharma sector in Q1 2025 witnessed deals worth $37.7 billion, an increment of 100.4% compared to Q4 2024. In terms of deal volume, there was a decline of 1.4% to 142 M&A deals in Q1 2025. Oncology was the top therapy area with 63 deals, an increase of 6.8% YoY.
Scope
- This report provides an overview of M&A activity globally in Q1 2025 in the Pharma sector involving biopharmaceutical drug companies.
- It identifies key trends, and the most notable deals announced in Q1 2025 in the Pharma sector.
Reasons to Buy
- Companies that make strategic investments in M&A position themselves for success, while those that fail to adapt risk falling behind.
- This report provides an overview of global M&A trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.
Table of Contents
1 Table of Contents1.1 List of Tables
1.2 List of Figures
2 Pharma M&A Activity in Q1 2025
2.1 Pharma Insights: Deal spotlight
3 Global M&A Trends in Pharma
4 Global Quarterly M&A Activity in Pharma
5 Ownership Type: Private Vs Public (Count)
6 Ownership Type: Private Vs Public (Value)
7 Global M&A Activity in Pharma by Deal Size
8 Notable Pharma Deals in Q1 2025
9 Pharma Regional Comparison - Q1 2025
10 Global Cross Border M&A Trends in Pharma
11 Inbound and Outbound Deals in Pharma in Q1 2025
12 Regional M&A Activity in Pharma by Value and Volume
13 Pharma M&A Review by Top 10 Countries
14 Top 10 Therapy Area M&A Review
16 Further Information
16.1 Methodology
17 Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Anthos Therapeutics
- Araris Biotech
- Chimerix
- EsoBiotec
- Evergreen Theragnostics
- IDRx
- Intra-Cellular Therapies
- Mayne Pharma
- Mitsubishi Tanabe Pharma
- Nanyue Biopharming
- Shanghai Hutchison Pharmaceuticals
